New combo therapy shows promise in controlling advanced lung cancer
NCT ID NCT02587455
First seen May 12, 2026 · Last updated May 25, 2026 · Updated 3 times
Summary
This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiotherapy is safe for people with advanced lung cancer. 24 participants received both treatments, then continued pembrolizumab alone. The goal was to find the safest dose and see if the combination could slow cancer growth. The study focused on safety and tumor control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THORACIC TUMOURS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
London, SW3 6JJ, United Kingdom
-
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.